Decoding ALS: Clinical Insights from a 56-Year-Old Male Case
Abstract
Keywords
Full Text:
PDFReferences
Brown, R. H., & Al-Chalabi, A. (2017). Amyotrophic Lateral Sclerosis. *The New England Journal of Medicine, 377*(2), 162-172. https//doi.org/10.1056/NEJMra1603471.
van Es, M. A., Hardiman, O., Chio, A., Al-Chalabi, A., Pasterkamp, R. J., Veldink, J. H., & van den Berg, L. H. (2017). Amyotrophic Lateral Sclerosis. *The Lancet, 390*(10107), 2084-2098. https//doi.org/10.1016/S0140-6736(17)31287-4.
Taylor, J. P., Brown, R. H., & Cleveland, D. W. (2016). Decoding ALS: From Genes to Mechanism. *Nature, 539*(7628), 197-206. https//doi.org/10.1038/nature20413.
Ghasemi, M., Brown, R. H., & Garbern, J. Y. (2021). Genetics of Amyotrophic Lateral Sclerosis. *Cold Spring Harbor Perspectives in Medicine, 8*(2), a024125. https://doi.org/10.1101/cshperspect.a024125.
Chio, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., & Traynor, B. G. (2009). Prognostic Factors in ALS: A Critical Review. *Amyotrophic Lateral Sclerosis, 10*(5-6), 310-323. https//doi.org/10.3109/17482960903211272.
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012). Riluzole for Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND). *Cochrane Database of Systematic Reviews, 3*. https://doi.org/10.1002/14651858.CD001447.pub3.
Abe, K., Aoki, M., Tsuji, S., Itoyama, Y., Sobue, G., Yasuda, N., ... & Yoshino, H. (2014). Safety and Efficacy of Edaravone in Well Defined Patients with Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial. *Lancet Neurology, 16*(7), 505-512. https://doi.org/10.1016/S1474-4422(17)30115-1.
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., ... & Zoing, M. C. (2011). Amyotrophic Lateral Sclerosis. *The Lancet, 377*(9769), 942-955. https://doi.org/10.1016/S0140-6736(10)61156-7.
Ludolph, A. C., Lücking, C. H., & Kassubek, J. (2012). MRI-Based Neuroimaging in ALS. *Current Opinion in Neurology, 25*(5), 524-529. https://doi.org/10.1097/WCO.0b013e328357a1bc.
Talbot, K. (2009). Motor Neuron Disease: The Bare Essentials. *Practical Neurology, 9*(5), 303-309. https//doi.org/10.1136/jnnp.2009.183541.
Strong, M. J., Abrahams, S., Goldstein, L. H., Woolley, S., McLaughlin, P., Snowden, J., ... & Turner, M. R. (2017). Amyotrophic Lateral Sclerosis – Frontotemporal Spectrum Disorder (ALS-FTSD): Revised Diagnostic Criteria. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18*(3-4), 153-174. https//doi.org/10.1080/21678421.2016.1267768.
Byrne, S., Walsh, C., Lynch, C., Bede, P., Elamin, M., Kenna, K., ... & Hardiman, O. (2011). Rate of Deterioration in Amyotrophic Lateral Sclerosis: A Clinic Population-Based Study. *Journal of Neurology, Neurosurgery & Psychiatry, 82*(6), 640-646. https://doi.org/10.1136/jnnp.2010.223750.
Renton, A. E., Chio, A., & Traynor, B. J. (2014). State of Play in Amyotrophic Lateral Sclerosis Genetics. *Nature Neuroscience, 17*(1), 17-23. https://doi.org10.1038/nn.3584.
Gordon, P. H., Miller, R. G., & Moore, D. H. (2004). ALS Care and Clinical Trials: Does Site Matter? *Journal of Neurology, Neurosurgery & Psychiatry, 75*(5), 756-760. https://doi.org/10.1136/jnnp.2003.028407.
Brooks, B. R. (1994). El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. *Journal of the Neurological Sciences, 124*(1), 96-107. https://doi.org/10.1016/0022-510X(94)90191-0.
Benatar, M., Wuu, J., McLean, R., Andersson, P., & Tremblay, J. P. (2016). The Benefit of Dual Drug Therapy in ALS: A Study of Riluzole and Sodium Phenylbutyrate Combined. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17*(5-6), 294-301. https://doi.org/10.3109/21678421.2016.1161372.
Nijssen, J., Comley, L. H., & Hedlund, E. (2017). Motor Neuron Vulnerability and Resistance in Amyotrophic Lateral Sclerosis. *Acta Neuropathologica, 133*(6), 863-885. https://doi.org/10.1007/s00401-017-1708-8
Logroscino, G., Traynor, B. J., Hardiman, O., Chiò, A., Mitchell, D., Swingler, R. J., Millul, A., Benn, E., & Beghi, E. (2009). Incidence of amyotrophic lateral sclerosis in Europe. Journal of Neurology Neurosurgery & Psychiatry, 81(4), 385–390. https://doi.org/10.1136/jnnp.2009.183525
Puopolo, M., Bacigalupo, I., Piscopo, P., Lacorte, E., Di Pucchio, A., Santarelli, M., Inghilleri, M., Petrucci, A., Sabatelli, M., & Vanacore, N. (2021). Prevalence of amyotrophic lateral sclerosis in Latium region, Italy. Brain and Behavior, 11(12). https://doi.org/10.1002/brb3.2378
Longinetti, E., & Fang, F. (2019). Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Current Opinion in Neurology, 32(5), 771–776. https://doi.org/10.1097/wco.0000000000000730
Incidence of ALS in Italy. (2001b). Neurology, 56(2), 239–244. https://doi.org/10.1212/wnl.56.2.239
Arthur, K. C., Calvo, A., Price, T. R., Geiger, J. T., Chiò, A., & Traynor, B. J. (2016b). Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nature Communications, 7(1). https://doi.org/10.1038/ncomms12408
DOI: http://dx.doi.org/10.52155/ijpsat.v45.2.6510
Refbacks
Copyright (c) 2024 Savitran Eshwar, Netra Agarwal

This work is licensed under a Creative Commons Attribution 4.0 International License.